Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-10-16
2007-10-16
Kaushal, Sumesh (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S044000, C435S069100, C435S320100, C435S325000, C435S455000
Reexamination Certificate
active
10495893
ABSTRACT:
This invention provides a method for reducing the amount of osteopontin in an osteopontin-expressing cell comprising introducing into the cell a nucleic acid which specifically inhibits osteopontin expression in the cell. This invention also provides methods for inhibiting the onset of, and treating, osteopontin-related disorders, as well as compositions for practicing the same. This invention further provides methods for determining the amount of osteopontin in a sample, and a kit for practicing the same. This invention also provides methods for determining whether an agent reduces the amount of osteopontin in an osteopontin-expressing cell. Finally, this invention provides methods for treating a subject afflicted with a disorder mediated by an endogenous protein.
REFERENCES:
patent: 5695761 (1997-12-01), Denhardt et al.
patent: WO 01/26679 (2001-04-01), None
patent: WO 01/71358 (2001-09-01), None
patent: WO 02/092122 (2002-11-01), None
Goncalves, Bioessays, 2005, 27: 506-517.
Ashkar, S. et al., “Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity,”Science, 287:860-864 (Feb. 4, 2000).
Becker, K. et al., “Analysis of a sequenced cDNA library from multiple sclerosis lesions,”J. Neuroimmunol., 77(1):27-38 (Jul. 1997).
Bell, J. and Lathrop, G.M., “Multiple loci for multiple sclerosis,”Nat. Genet., 13(4):464-468 (Aug. 1996).
Brocke, S. et al., “Antibodies to CD44 and integrin α4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment,”Pro.c Natl. Acad. Sci. U S A, 96(12):6896-6901 (Jun. 8, 1999).
Chabas, D. et al., “The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease,”Science, 294:1731-1735 (Nov. 23, 2001).
Choi, S.S. et al., “Construction of a gene expression profile of a human fetal liver by single-pass cDNA sequencing,”Mamm. Genome., 6(9):653-657 (Sep. 1995).
Denhardt, D. and Guo, X., “Osteopontin: a protein with diverse functions,”FASEB J., 7(15):1475-1482 (Dec. 1993).
Denhardt, D.T. et al., “Osteopontin ad a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival,”J. Clin Invest., 107(9):1055-1061 (May 2001).
Ebers, G. et al., “A full genome search in multiple sclerosis,”Nat. Genet., 13(4):472-476 (Aug. 1996).
Fisher, L. et al., “Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin,”Biochem. Biophys. Res. Commun., 280(2):460-465 (Jan. 19, 2001).
Gijbels, K. et al., “Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation,”Mol. Med., 1(7):795-805 (Nov. 1995).
Haines, J. et al., “A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group,”Nat. Genet., 13(4):469-71 (Aug. 1996).
Hwang, S.M. et al., “Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells,”J. Biol. Chem., 269(1):711-715 (Jan. 7, 1994).
Karin, N. et al., “Short peptide-based tolerogens without self-antigenic or pathogenic activity reverse autoimmune disease,”J. Immunol., 160(10):5188-5194 (May 15, 1998).
Oldberg, A. et al., “Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence,”Proc. Natl. Acad. Sci. USA, 83(23):8819-8823 (Dec. 1986).
O'Regan, A.W. et al., “Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks,”Immunol. Today., 21(10):475-478 (Oct. 2000).
Pedotti, R. et al., “An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide,”Nat. Immunol., 2(3):216-222 (Mar. 2001).
Pitt, D. et al., “Glutamate excitotoxicity in a model of multiple sclerosis,”Nat. Med., 6(1):67-70 (Jan. 2000).
Rittling, S.R. and Denhardt, D.T., “Osteopontin function in pathology: lessons from osteopontin-deficient mice,”Exp. Nephrol., 7(2):103-113 (Mar.-Apr. 1999).
Rittling, S.R. et al., “Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro,”J. Bone Miner. Res., 13(7):1101-1111 (Jul. 1998).
Sasaki, N. et al. “Characterization of gene expression in mouse blastocyst using single-pass sequencing of 3995 clones,”Genomics, 49(2):167-179 (Apr. 15, 1998).
Shin, S.L. et al., “Expression of osteopontin mRNA in the adult rat brain,”Neurosci. Lett., 273(2):73-76 (Oct. 1, 1999).
Sobel, R. et al., “Vitronectin and integrin vitronectin receptor localization in multiple sclerosis lesions,”J. Neuropathol. Exp. Neurol., 54(2):202-213 (Mar. 1995).
Steinman, L., “Immunotherapy of multiple sclerosis: the end of the beginning,”Current Opinion in Immunology, 13:597-600 (2001).
Steinman, L., “Multiple sclerosis: a two-stage disease,”Nat. Immunology, 2(9):762-764 (Sep. 2001).
Trapp, B. et al., “Axonal transection in the lesions of multiple sclerosis,”N. Engl. J. Med., 338(5):278-285 (Jan. 29, 1998).
Verma, I. and Nikunj, S., “Gene therapy—promises, problems and prospects,”Nature, 389:239-242, Sep. 18, 1997.
Villarroya, H. et al., “Expression of TNFα in central neurons of Lewis rat spinal cord after EAE induction,”J. Neurosci. Res., 49(5):592-599 (Sep. 1, 1997).
Young, M. et al., “cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN),”Genomics, 7(4):491-502 (Aug. 1990).
Chabas Dorothee
Steinman Lawrence
Hiriyanna Kelaginamane T.
Kaushal Sumesh
The Board of Trustees of the Leland Stanford Junior University
Townsend & Townsend and Crew LLP
LandOfFree
Osteopontin-related compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Osteopontin-related compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Osteopontin-related compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3895410